Drug Discontinuation


HPS Pharmacies wish to advise that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), has given notice of the discontinuation of Zinbryta® as follows:

Zinbryta® 150mg/mL
Daclizumab 150mg/mL Pre-Filled Pen
ARTG 243873

Zinbryta® 150mg/mL
Daclizumab 150mg/mL Pre-Filled Syringe
ARTG 243872

The decision to withdraw Zinbryta® from the Australian market follows reports of serious inflammatory brain disorders in Europe. The TGA has not received any reports of inflammatory brain disorders occurring in Australian patients prescribed Zinbryta®.

Zinbryta® will continue to be supplied in Australia until 31st May 2018. Patients who are currently prescribed Zinbryta® should discuss future treatment options with their treating neurologist. Patients should also be advised that adverse reactions can occur up to six months after discontinuation. Patients discontinuing Zinbryta® should be encouraged to contact their doctor immediately if they develop new symptoms such as prolonged fever, serious headache, nausea or vomiting.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Biogen Australia on 02 8875 3900.

Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates